Multivisceral surgeries significantly improve survival in gastric cancer patients, indicating the benefit of adjuvant chemotherapy.
Key Points
Survival rates increased significantly with adjuvant chemotherapy, showing 50% five-year survival in patients with it.
Complications, particularly pancreatic fistulas, were more frequent in those undergoing pancreaticoduodenectomy compared to partial resection.
Multivisceral surgeries combined with pancreaticoduodenectomy offered better overall survival for patients in ASA class 1-2.
Negative factors affecting long-term prognosis included locoregional recurrence and women, while positive factors were the surgical approach and chemotherapy.